BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

470 related articles for article (PubMed ID: 23297719)

  • 1. Selection for hepatic resection of colorectal liver metastases: expert consensus statement.
    Adams RB; Aloia TA; Loyer E; Pawlik TM; Taouli B; Vauthey JN; ; ;
    HPB (Oxford); 2013 Feb; 15(2):91-103. PubMed ID: 23297719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Diagnosis and treatment of colorectal liver metastases - workflow].
    Grundmann RT; Hermanek P; Merkel S; Germer CT; Grundmann RT; Hauss J; Henne-Bruns D; Herfarth K; Hermanek P; Hopt UT; Junginger T; Klar E; Klempnauer J; Knapp WH; Kraus M; Lang H; Link KH; Löhe F; Merkel S; Oldhafer KJ; Raab HR; Rau HG; Reinacher-Schick A; Ricke J; Roder J; Schäfer AO; Schlitt HJ; Schön MR; Stippel D; Tannapfel A; Tatsch K; Vogl TJ;
    Zentralbl Chir; 2008 Jun; 133(3):267-84. PubMed ID: 18563694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Usefulness of contrast-enhanced intraoperative ultrasound in identifying disappearing liver metastases from colorectal carcinoma after chemotherapy.
    Arita J; Ono Y; Takahashi M; Inoue Y; Takahashi Y; Saiura A
    Ann Surg Oncol; 2014 Jun; 21 Suppl 3():S390-7. PubMed ID: 24570378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selection for hepatic resection: expert consensus conference.
    Rees M; Elias D; Coimbra FJ; Orloff SL; ; ;
    HPB (Oxford); 2013 Feb; 15(2):104-5. PubMed ID: 23297720
    [No Abstract]   [Full Text] [Related]  

  • 5. Early PET/CT scan is more effective than RECIST in predicting outcome of patients with liver metastases from colorectal cancer treated with preoperative chemotherapy plus bevacizumab.
    Lastoria S; Piccirillo MC; Caracò C; Nasti G; Aloj L; Arrichiello C; de Lutio di Castelguidone E; Tatangelo F; Ottaiano A; Iaffaioli RV; Izzo F; Romano G; Giordano P; Signoriello S; Gallo C; Perrone F
    J Nucl Med; 2013 Dec; 54(12):2062-9. PubMed ID: 24136935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases.
    Chun YS; Vauthey JN; Boonsirikamchai P; Maru DM; Kopetz S; Palavecino M; Curley SA; Abdalla EK; Kaur H; Charnsangavej C; Loyer EM
    JAMA; 2009 Dec; 302(21):2338-44. PubMed ID: 19952320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection.
    Wong R; Cunningham D; Barbachano Y; Saffery C; Valle J; Hickish T; Mudan S; Brown G; Khan A; Wotherspoon A; Strimpakos AS; Thomas J; Compton S; Chua YJ; Chau I
    Ann Oncol; 2011 Sep; 22(9):2042-2048. PubMed ID: 21285134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus.
    Adam R; De Gramont A; Figueras J; Guthrie A; Kokudo N; Kunstlinger F; Loyer E; Poston G; Rougier P; Rubbia-Brandt L; Sobrero A; Tabernero J; Teh C; Van Cutsem E;
    Oncologist; 2012; 17(10):1225-39. PubMed ID: 22962059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perioperative chemotherapy with bevacizumab and liver resection for colorectal cancer liver metastasis.
    Chaudhury P; Hassanain M; Bouganim N; Salman A; Kavan P; Metrakos P
    HPB (Oxford); 2010 Feb; 12(1):37-42. PubMed ID: 20495643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of liver metastasis: is diffusion-weighted imaging needed in Gd-EOB-DTPA-enhanced MR imaging for evaluation of colorectal liver metastases?
    Tajima T; Akahane M; Takao H; Akai H; Kiryu S; Imamura H; Watanabe Y; Kokudo N; Ohtomo K
    Jpn J Radiol; 2012 Oct; 30(8):648-58. PubMed ID: 22836904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
    Folprecht G; Gruenberger T; Bechstein WO; Raab HR; Lordick F; Hartmann JT; Lang H; Frilling A; Stoehlmacher J; Weitz J; Konopke R; Stroszczynski C; Liersch T; Ockert D; Herrmann T; Goekkurt E; Parisi F; Köhne CH
    Lancet Oncol; 2010 Jan; 11(1):38-47. PubMed ID: 19942479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Value of DCE-MRI and FDG-PET/CT in the prediction of response to preoperative chemotherapy with bevacizumab for colorectal liver metastases.
    De Bruyne S; Van Damme N; Smeets P; Ferdinande L; Ceelen W; Mertens J; Van de Wiele C; Troisi R; Libbrecht L; Laurent S; Geboes K; Peeters M
    Br J Cancer; 2012 Jun; 106(12):1926-33. PubMed ID: 22596235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver metastases from colorectal cancer treated with conventional and antiangiogenetic chemotherapy: evaluation with liver computed tomography perfusion and magnetic resonance diffusion-weighted imaging.
    Anzidei M; Napoli A; Zaccagna F; Cartocci G; Saba L; Menichini G; Cavallo Marincola B; Marotta E; Di Mare L; Catalano C; Passariello R
    J Comput Assist Tomogr; 2011; 35(6):690-6. PubMed ID: 22082538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic performance of MDCT, PET/CT and gadoxetic acid (Primovist(®))-enhanced MRI in patients with colorectal liver metastases being considered for hepatic resection: initial experience in a single centre.
    Chan VO; Das JP; Gerstenmaier JF; Geoghegan J; Gibney RG; Collins CD; Skehan SJ; Malone DE
    Ir J Med Sci; 2012 Dec; 181(4):499-509. PubMed ID: 22426901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imaging and treatment of patients with colorectal liver metastases in the Netherlands: a survey.
    Bipat S; van Leeuwen MS; Ijzermans JN; Bossuyt PM; Greve JW; Stoker J
    Neth J Med; 2006 May; 64(5):147-51. PubMed ID: 16702613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathological response after neoadjuvant bevacizumab- or cetuximab-based chemotherapy in resected colorectal cancer liver metastases.
    Pietrantonio F; Mazzaferro V; Miceli R; Cotsoglou C; Melotti F; Fanetti G; Perrone F; Biondani P; Muscarà C; Di Bartolomeo M; Coppa J; Maggi C; Milione M; Tamborini E; de Braud F
    Med Oncol; 2015 Jul; 32(7):182. PubMed ID: 26003673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selection of patients for resection of hepatic colorectal metastases: expert consensus statement.
    Charnsangavej C; Clary B; Fong Y; Grothey A; Pawlik TM; Choti MA
    Ann Surg Oncol; 2006 Oct; 13(10):1261-8. PubMed ID: 16947009
    [No Abstract]   [Full Text] [Related]  

  • 18. [Use of PET-CT in pre-surgical staging of colorectal cancer hepatic metastases].
    Ramos E; Martínez L; Gámez C; Torras J; Valls C; Rafecas A; Lladó L; Jorba R; Ruiz S; Serrano T; Fabregat J
    Cir Esp; 2008 Aug; 84(2):71-7. PubMed ID: 18682184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PET/CT in the evaluation of response to treatment of liver metastases from colorectal cancer with bevacizumab and irinotecan.
    Goshen E; Davidson T; Zwas ST; Aderka D
    Technol Cancer Res Treat; 2006 Feb; 5(1):37-43. PubMed ID: 16417400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selection of patients for resection of hepatic colorectal metastases: expert consensus statement by Charnsangavej et al.
    Chapman WC; Hoff PM; Strasberg SM
    Ann Surg Oncol; 2006 Oct; 13(10):1269-70. PubMed ID: 16952024
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 24.